Dr. Kidwell and colleagues reply

New England Journal of Medicine

Volumn 368, Issue 25, 2013, Pages 2434-2435

  Kidwell, Chelsea S ^a   Jahan, Reza ^b   Saver, Jeffrey L ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ANESTHESIA; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; ENDOVASCULAR SURGERY; HUMAN; LETTER; MEDICAL DEVICE; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECANALIZATION; STENT; FEMALE; MALE; METHODOLOGY; NOTE; THROMBECTOMY;

ENDOVASCULAR PROCEDURES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; NEUROIMAGING; STROKE; THROMBECTOMY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84879080700     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1304759     Document Type: Letter

References (4)

1. Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012;11:860-7.
2. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099-107.
3. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
4. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol 2006;60:508-17. (Pubitemid 44871793)